Home » UL Announces Expanded Testing for Drug Contaminants in Treated Wastewater
UL Announces Expanded Testing for Drug Contaminants in Treated Wastewater
UL combined its existing methods (L200, L211, L220 & L221) to develop UL test method L222 used for the analysis of Endocrine Disrupting Chemicals (EDCs) and PPCPs. This method focuses on detecting and analyzing nearly 30 most frequently studied and detected contaminants of emerging concern including acetaminophen, bisphenol A, caffeine, DEET, estrone, nicotine, nonylphenol, triclosan, etc. UL also streamlined the analysis of selected semi-volatile organic compounds including sterols, phosphate flame retardants, fragrances, polyaromatic hydrocarbons (PAHs), phenols, and pesticides to create UL method S190. Both the L222 and S190 testing methods are used to analyze contaminants of emerging concern found in treated wastewater, surface water, groundwater and municipal drinking water.
According to a report from IMS Health, a leading provider of market intelligence to the pharmaceutical and healthcare industries, in 2009 global pharmaceutical sales exceeded $773 billion. As a result, the consumption of PPCPs has increased significantly over the last 20 years triggering a rise in the amount of PPCPs entering water supplies through excretion, bathing and the disposal of medications in sewers and trash. Today, UL analytical capabilities include analysis of nearly 120 emerging contaminants including EDCs, PPCPs, flame-retardants, and other contaminants of emerging concern.
“The human health and environmental effects associated with PPCPs in water supplies are not well understood at this time,” said Dennis Leeke, Business Manager, UL Global Water Business. “UL recognizes the importance of this growing issue and is one of only a few laboratories in the country that has developed methods to detect pharmaceuticals and other compounds at ultralow levels. We are committed to supporting the drinking water industry by providing water utilities and government agencies with new ways to detect and analyze emerging contaminants more accurately than ever before.”
As a global leader in drinking water quality and safety, UL has analyzed more than two million drinking water samples for thousands of public and private entities, including the U.S. Environmental Protection Agency. UL tests water representing more than 7,000 municipalities and is certified in 48 states and Puerto Rico. The company also is an approved certifier of water products that meet the criteria of the EPA’s WaterSenseSM program, which identifies and promotes the use of water-efficient products. For more information on UL’s water programs and services, visit the water industry section on www.ul.com.
About Underwriters Laboratories
UL is an independent product safety certification organization that has been testing products and writing Standards for Safety for more than a century. UL evaluates more than 19,000 types of products, components, materials and systems from more than 66,000 manufacturers each year. In total, there are more than 20 billion UL Marks appearing on products worldwide. UL's global family of companies and network of service providers includes 68 laboratory, testing and certification facilities serving customers in 102 countries. For more information, visit: http://www.ul.com/newsroom.
French Drugmaker on Trial for Suspected DeathsFrom Yahoo! News
Servier Laboratories, French drugmaker responsible for producing diabetes and weight loss drug Mediator, faces charges for deception in relation to the suspected deaths of hundreds of people.
Novo Acquires Xellia Pharmaceuticals for $700 MillionFrom PharmaTimes Online
Novo A/S has acquired Xellia Pharmaceuticals of Norway
Royalty Increases Bid as Elan Unveils AcquisitionsFrom PharmaTimes Online
Royalty Pharma has resurfaced to raise its bid to acquire the Irish drugmaker Elan
New Asthma Drug Offers Hope for PatientsFrom Forbes
An experimental asthma drug could give new hope to patients for whom existing medicines are not enough
Syrian Pharma Production Nearly Halted by WarFrom AFP
A shortage of foreign currency has brought production to a near halt in Syria
Camfil APC Opens Manufacturing Plant in the UKFrom Camfil
Camfil announced the grand opening of its new 40,000-sq.-ft. facility
Actavis Acquiring Warner Chilcott for $8.5BFrom AP
Actavis to buy Warner Chilcott in an all-stock transaction
Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics
NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration
Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com
Agreement creates unique strategic collaboration for development and clinical trial execution
$15 Billion Myland Offer Rejected By ActavisFrom Bloomberg.com
Actavis has rejected drugmaker Mylan Inc's cash-and-stock offer for $15 billion. They have decided to continue talks to take over Warner Chilcott Plc instead, sources have said.
- All news »